Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.

You may also be interested in...



Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch

Firm pays $150 million for the topical acne treatment; QLT continues sale of assets.

Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch

Firm pays $150 million for the topical acne treatment; QLT continues sale of assets.

QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne

Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel